Table I.
Association between tumor necrosis factor receptor 2 and clinical parameters of patients with breast cancer.
TNFR2 expression, n | ||||
---|---|---|---|---|
Clinical parameters | Cases, n | Low | High | P-value |
Total | 125 | 71 | 54 | |
Age | 0.788 | |||
<35 years | 40 | 22 | 18 | |
≥35 years | 85 | 49 | 36 | |
Menopausal status | 0.156 | |||
No | 49 | 24 | 25 | |
Yes | 76 | 47 | 29 | |
Family history | 0.245 | |||
No | 105 | 62 | 43 | |
Yes | 20 | 9 | 11 | |
Tumor size | 0.006a | |||
<5 cm | 109 | 67 | 42 | |
≥5 cm | 16 | 4 | 12 | |
Lymph node involvement | 0.188 | |||
No | 61 | 31 | 30 | |
Yes | 64 | 40 | 24 | |
Clinical stage | 0.011a | |||
I/II | 93 | 59 | 34 | |
III | 32 | 12 | 20 | |
Pathological grade | 0.004a | |||
G1/G2 | 106 | 66 | 40 | |
G3 | 19 | 5 | 14 | |
Pathological type | 0.379 | |||
Ductal invasive | 84 | 50 | 34 | |
Others | 41 | 21 | 20 | |
ER, PR and HER2 status | 0.607 | |||
Triple-negative | 33 | 20 | 13 | |
Non-triple-negative | 92 | 51 | 41 |
P<0.05. TNFR2, tumor necrosis factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.